NeuraLight, a company focused on developing precision biomarkers for neurological diseases, has announced the appointment of Nobel Prize winning neuroscientist Professor Thomas Südhof as Scientific Co founder and member of its Scientific Advisory Board. The announcement follows the recent confirmation that Professor Olivier Rascol, a globally recognized neurologist and one of the architects of the MDS UPDRS scale for Parkinson’s disease progression, will serve as Chair of the Scientific Advisory Board.
Health Technology Insights: The Dot Corp Partners with ixlayer to Advance Direct-to-Patient Kitting & Fulfillment for Biopharma
The expanded board brings together exceptional clinical and scientific expertise that will support NeuraLight’s validation focused strategy. The company has already demonstrated movement based disease progression measures that are significantly more sensitive than traditional clinical scales. Board members will contribute to advancing clinical validation, supporting integration into pharmaceutical trials, and guiding the broader rollout of NeuraLight’s precision measurement platform across neurological indications.
Professor Thomas Südhof received the Nobel Prize in Physiology or Medicine in 2013 for his discoveries related to synaptic transmission. He currently leads the Südhof Laboratory at Stanford University. In his role at NeuraLight, he will oversee the scientific foundations of the company’s biomarker development and support ongoing work in Alzheimer’s disease and other neurological disorders. Having advised the company during its early research phase, he now formally joins as Scientific Co founder and board member.
Professor Olivier Rascol brings more than three decades of leadership in Parkinson’s disease research, with extensive experience in motor progression, disease modification, and clinical trial methodology. He is a Professor of Clinical Pharmacology at Toulouse University Hospital and has led recent studies exploring novel therapeutic approaches in Parkinson’s disease. At NeuraLight, he will help shape scientific direction and expand the clinical relevance of the company’s biomarker platform as it scales across therapeutic areas.
The board also includes Professor Alvin Roth, a Nobel Prize laureate in Economics and Professor at Stanford University. Professor Roth is widely known for his work in market design, including applications in healthcare. He will advise NeuraLight on value based collaboration models, ecosystem development, and strategic partnerships with healthcare stakeholders.
Health Technology Insights: Seegene Establishes French Subsidiary to Expand European Footprint
Edmund Ben Ami, Chief Executive Officer and co founder of NeuraLight, said the company is honored to welcome such respected scientific leaders. He noted that their involvement reinforces confidence in NeuraLight’s technology and will be instrumental in advancing clinical validation efforts and strengthening collaborations with pharmaceutical partners. According to Ben Ami, the appointments further support the company’s mission to redefine how disease progression is measured in neurology.
NeuraLight’s platform is built on decades of research linking eye movements and brain function. The company has developed a brief tablet based assessment that generates objective biomarkers capable of detecting subtle disease changes often missed by conventional methods. The technology is currently being used in clinical collaborations worldwide, involving more than twelve hundred patients across conditions including Parkinson’s disease, ALS, multiple sclerosis, and Huntington’s disease, as well as in multiple commercial drug trials.
Professor Rascol commented that he has been impressed by the robustness of NeuraLight’s validation data. He explained that while clinical scales remain useful, they can lack precision, and imaging approaches are often expensive and complex. He highlighted that eye movement based biomarkers offer objective and quantitative insights into disease severity and progression.
Supporting the core board are several senior scientific advisors. These include Professor Cristina Sampaio, Chief Medical Officer of the Cure Huntington’s Disease Initiative Foundation and Professor of Clinical Pharmacology at the University of Lisbon, Professor Fred Lublin, Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai in New York, and Professor Chris Goetz, a co creator of the MDS UPDRS and Director of the Movement Disorders Program at Rush University Medical Center. Together, this group reinforces NeuraLight’s scientific depth as it continues to transform neurological disease progression measurement.
Health Technology Insights: B. Braun Launches Piperacillin-Tazobactam in DUPLEX System
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
